Liver Cancer Medicines: Generic Hepatocellular Carcinoma Treatment
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. OnlineMeds offers FDA-approved generic targeted therapies and multi-kinase inhibitors for advanced HCC—at 86–90% savings compared to branded versions. Our portfolio includes both first-line and second-line treatment options.
Our Liver Cancer Treatment Options
- Sorafenib (Nexavar) — First-line multi-kinase inhibitor for advanced HCC
- Lenvatinib (Lenvima) — First-line VEGF receptor inhibitor for HCC
- Regorafenib (Stivarga) — Multi-kinase inhibitor for sorafenib-resistant HCC
- Cabozantinib (Cometriq) — Second-line TKI for advanced HCC
- Atezolizumab + Bevacizumab — Immunotherapy combinations (specialty orders)
How These Medicines Work
HCC targeted therapies block growth factor pathways that drive tumor progression. Sorafenib and lenvatinib inhibit VEGF and FGF receptors, cutting off tumor blood supply and stopping cell proliferation. Regorafenib and cabozantinib target additional kinases to overcome resistance. These approaches extend survival and improve quality of life in advanced disease.
Why Choose OnlineMeds for HCC Medications?
- FDA-approved generic Nexavar (sorafenib) and Lenvima (lenvatinib)
- Save 86–90% on liver cancer therapies
- Prescription verification at checkout
- Secure international delivery
- Patient education and support materials included
Frequently Asked Questions
Q: What is the standard treatment for advanced hepatocellular carcinoma?
A: Sorafenib and lenvatinib are both established first-line options for unresectable HCC. Your hepatologist or oncologist will choose based on liver function, performance status, and your specific case. This is educational information only.
Q: How is HCC stage determined?
A: HCC is staged using the Barcelona Clinic Liver Cancer (BCLC) classification and TNM staging. Early-stage disease may be candidates for surgery or transplant; advanced (BCLC C) cases typically receive sorafenib or lenvatinib.
Q: What side effects should I monitor?
A: Hand-foot skin reaction, diarrhea, hypertension, and fatigue are common. Liver function must be monitored closely, as some patients experience reduced tolerance. Your team will adjust dosing if needed.
Q: Can I take HCC medicines if I have cirrhosis?
A: Yes, but dosing may be adjusted based on liver function tests. Child-Pugh score influences treatment decisions. Always discuss your complete medical history with your hepatologist.
Q: How long will treatment continue?
A: Treatment typically continues as long as the cancer responds and side effects are manageable. Regular imaging (CT/MRI every 4–6 weeks) guides continuation decisions.
Q: What if my cancer progresses on sorafenib?
A: Progression on first-line therapy indicates regorafenib or cabozantinib as second-line options. We can source these medications rapidly. Consult your oncologist about your next steps.
Medical Disclaimer
This content is for informational purposes only and is not intended as medical advice or diagnosis. Hepatocellular carcinoma is a complex disease requiring specialist hepatologic and oncologic care. Always use HCC medicines exactly as prescribed by your licensed hepatologist or oncologist. If you have questions about your treatment, consult your doctor or pharmacist immediately.